Showing 2341-2350 of 9328 results for "".
Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of itsEmrosi Launched in the US for Rosacea
https://practicaldermatology.com/videos/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.SCALE 2024: Dr. Michelle Henry on Innovative Skincare Products and Lasers in Skin of Color
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michelle-henry-innovative-skincare-products-and-lasers-skin-color/26374/Michelle Henry, MD, discusses innovative skincare products and lasers in skin of color, including her top 10 tips for ensuring best outcomes and reducing adverse events, at Music City SCALE.Noah Worcester 2024: Dr. Brodell on Microscopes
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-brodell-microscopes/24579/Robert Brodell, MD, summarizes his lecture on Santa Cruz Antique Microscope Collection at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, tGuselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Hair Today
https://practicaldermatology.com/conferences/scale-2023/hair-today/20204/Joel L. Cohen, MD, and Doris Day, MD, discuss the latest advances in treating hair loss including the use of lasers with topicals, supplements, or PRP injections. They also discuss some of the risks associated with the use of biotin as a hair growth supplement.Recognizing Dermatologic Emergencies in Kids
https://practicaldermatology.com/conferences/scale-2023/recognizing-dermatologic-emergencies-in-kids/20198/Infections including congenital infections, syphilis, or HSV are the No. 1 cause of pediatric skin emergencies. Infantile hemangiomas in the airway can affect breathing and also require fast and early treatment, explains Thy Huynh, MD.DermWireTV: USPSTF Tackles Racism; Winlevi Launch; Derm Days in Focus
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-uspstf-tackles-racism-winlevi-launch-derm-days-in-focus/20014/The US Preventive Services Task Force is undertaking efforts to mitigate the influence of systemic racism in its recommendations. Global Psoriasis Day, National Biologics Coordinators Day, and Retinol Day bring attention to skin issues. Sun Pharmaceutical’s Winlevi (clascoterone) cream 1% is now avaNew Topical Options for Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-topical-options-for-psoriasis/19979/Leon Kircik, MD shares his excitement about new molecules for psoriasis. He discusses the available data for tapinarof, a first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, and roflumilast cream, a once-daily topical formulation of roflumilast, a high